Abstract
Background: In patients with chronic kidney disease, metabolic syndrome has been demonstrated to be the culprit behind diverse complications. Adiponectin is known to have anti-atherogenic and cardio-protective effects. Meanwhile, the relationship between adiponectin and metabolic syndrome in patients with chronic kidney disease has not been clarified. The aim of this study was to elucidate the relationship between adiponectin level and metabolic syndrome in patients with chronic kidney disease. Methods: The KoreaN Cohort Study for Outcome in Patients with Chronic Kidney Disease is a cohort study that enrolled subjects with chronic kidney disease throughout South Korea. From February 2011 to July 2014, data were collected from 1332 patients with chronic kidney disease. Results: The mean age of the patients was 53.5 years and 803 patients (60.7%) were men. The median adiponectin level was 10.7 μg/mL and 585 (44.3%) patients had metabolic syndrome. In multiple linear regression analysis, log adiponectin was positively associated with high-density lipoprotein cholesterol levels (β = 0.006), whereas it was negatively associated with serum albumin (β = −0.284), triglyceride (log β = −0.288), high sensitivity C-reactive protein (log β = −0.058) levels and estimated glomerular filtration rate (β = −0.005). Multiple logistic regression analysis indicated that low adiponectin level was independently associated with a higher risk of metabolic syndrome (per 1 μg/mL increase; odds ratio = 0.953, 95% confidence interval = 0.898-0.970, P < 0.001) after adjustment for multiple confounding factors. Conclusions: Hypoadiponectinemia is independently associated with the presence of metabolic syndrome in patients with chronic kidney disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1-10 |
| Number of pages | 10 |
| Journal | Diabetology and Metabolic Syndrome |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2016 Nov 14 |
Bibliographical note
Funding Information:The authors acknowledge all of the patients who participated in the KNOW‑ CKD and the investigators who took part in data collection. This work was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (2011E3300300, 2012E3301100, 2013E3301600). The KNOW-CKD Investigator Group Patient Recruitment. Seoul National University Hospital, Curie Ahn, MD (PI), Kook‑Hwan Oh, MD (SubPI), Hajeong Lee, MD, Seungmi Lee, RN, Jiseon Kim, RN, and Aram Lee, RN. Seoul National University Bundang Hospital, Dong Wan Chae, MD (SubPI), Seon Ha Baek MD, and Hyun Jin Cho, RN. Yonsei University, Severance Hospital, Kyu Hun Choi, MD (SubPI), Seung Hyeok Han, MD, Tae Hyun Yoo, MD, and Mi Hyun Yu, RN. Kangbuk Samsung Hospital, Kyu‑Beck Lee, MD and Young Youl Hyun, MD. The Catholic University of Korea, Seoul St. Mary’s Hospital, Yong‑Soo Kim, MD and Min Jung Ahn, RN. Gachon University, Gil Hospital, Wookyung Chung, MD, Ji Yong Jung, MD, Youkyoung Jang, RN, and Ji Hye Park, RN. Eulji Medical Center, Eulji
Publisher Copyright:
© 2016 The Author(s).
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
